Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.00
0% from low
Exchange
OTC Link
OS
Borrow rate
66.47%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.5K | $130.7K | $33.5K | $81.7K | $45.5K | $3.2K | $0 | $0 |
| Cost of revenue | $0 | $0 | $142.0K | $0 | $0 | $0 | $536.2K | $962.3K |
| Gross profit | $0 | $130.7K | −$108.5K | $81.7K | $45.5K | $3.2K | −$536.2K | −$962.3K |
| Gross margin | 0.0% | 100.0% | -324.1% | 100.0% | 100.0% | 100.0% | — | — |
| R&D | $3.3M | $4.1M | $5.9M | $12.7M | $14.6M | $22.3M | $24.5M | $22.4M |
| Operating income | −$6.3M | −$8.3M | −$12.5M | −$21.8M | −$22.4M | −$35.3M | −$40.2M | −$38.7M |
| EBITDA | −$6.0M | −$8.2M | −$8.7M | −$21.5M | −$19.6M | −$28.3M | −$36.4M | −$35.5M |
| Net income | −$6.3M | −$9.0M | −$12.2M | −$21.9M | −$21.1M | −$27.4M | −$36.3M | −$36.5M |
| Net margin | -6765.4% | -6858.7% | -36447.1% | -26750.0% | -46381.7% | -868765.3% | — | — |
| EPS (diluted) | -2.30 | -2.84 | -3.15 | -5.00 | -4.25 | -4.55 | -4.89 | -4.37 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-2.60 | $-2.60–$-2.60 | 1 |
| 2027 | $115M | $-0.02 | $-0.02–$-0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
IMV INC
No one on the platform currently holds IMVIF.
No tracked institution reports a position in IMVIF as of their last filing.
No one on the platform has traded IMVIF yet.
| $107 |
| — |
| DMKPQDMK Pharmaceuticals Corporation | $0.00 | +0.00% | $1010 | — |
| EFTReFFECTOR Therapeutics, Inc. | $0.00 | +0.00% | $2823 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.